Excretion of metrizamide in milk

Ilett, K. F.; Hackett, L.P.; Paterson, J. W.; McCormick, C. C.

doi:10.1259/0007-1285-54-642-537

Cited by 29 publications

(8 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This corresponds to 0.5% of the maternal dose with iohexol and 0.3% of the maternal dose with metrizoate. Following metrizamide (5.06 mg) given intrathecally, only 0.02% of the dose was excreted in the milk by 44 h [57]. Even after fat-soluble cholecystographic agents, iodine excretion in the milk was very low [58].…”

Section: Iodinated Contrast Mediamentioning

confidence: 99%

The use of iodinated and gadolinium contrast media during pregnancy and lactation

Webb

Thomsen

Morcos³

2004

Eur Radiol

512

180

View full text Add to dashboard Cite

The use of iodinated or gadolinium-based contrast media in pregnant or lactating women often causes concerns in the radiology department because of the principle of not exposing a fetus or neonate to any drugs. Because of the uncertainty about the use of contrast media during pregnancy and lactation, the Contrast Media Safety Committee of the European Society of Urogenital Radiology decided to review the literature and draw up guidelines. An extensive literature search was carried out and summarized in a report. Based on the limited information available, simple guidelines have been drawn up. The report and guidelines were discussed at the 11th European Symposium on Urogenital Radiology in Santiago de Compostela, Spain. Mutagenic and teratogenic effects have not been described after administration of gadolinium or iodinated contrast media. Free iodide in radiographic contrast medium given to the mother has the potential to depress fetal/neonatal thyroid function. Neonatal thyroid function should be checked during the 1st week if iodinated contrast media have been given during pregnancy. No effect on the fetus has been seen after gadolinium contrast media. Only tiny amounts of iodinated or gadolinium-based contrast medium given to a lactating mother reach the milk, and only a minute proportion entering the baby's gut is absorbed. The very small potential risk associated with absorption of contrast medium may be considered insufficient to warrant stopping breast-feeding for 24 h following either iodinated or gadolinium contrast agents.

show abstract

Section: Iodinated Contrast Mediamentioning

confidence: 99%

The use of iodinated and gadolinium contrast media during pregnancy and lactation

Webb

Thomsen

Morcos³

2004

Eur Radiol

512

180

View full text Add to dashboard Cite

show abstract

“…ILETT et coli. (5) in 1981 found very small amounts of metrizamide in breast milk from one patient and FITz-JOHN et coli. (3) found undetectable amounts of diatrizoic acid and iodarnide, both ionic contrast media.…”

mentioning

confidence: 91%

Excretion of Iohexol and Metrizoate in Human Breast Milk

Nielsen

Matheson²,

Rasmussen³

et al. 1987

Acta Radiol

View full text Add to dashboard Cite

Six lactating women undergoing contrast media examination had milk and blood taken to determine the rate and extent of excretion of iohexol (Omnipaque) (four mothers) and metrizoate (Isopaque) (two mothers). Blood samples were taken up to 45 minutes and milk samples up to 48 hours after the contrast medium injection. The excretion was low, reaching a maximum at 3 to 6 hours and showing a slow decay curve (tt = 15 to 108 hours). One mother, who was weaning her baby, showed a different excretion pattern. The amount excreted during 24 hours was about 0.5 per cent of the weight adjusted maternal dose for both iohexol and metrizoate. It is not likely, that such a low dose of poorly absorbed drug would cause any adverse effects in the infant, unless it is hypersensitive to the drug already. The authors consider breast feeding to be acceptable for mothers receiving iohexol or metrizoate.

show abstract

“…Most of the analysed ICMs (metrizoate, iodamide, metrizamide, and iopanoic acid) have been discontinued (table 1). The total number of patients investigated in six papers [5][6][7][8][9][10] was only twenty-two. Following the subtraction of patients receiving compounds that are no longer on the market, a group of seven patients remains (four received iohexol, and three amidotrizoate) as basis for the guidelines [1,2].…”

mentioning

confidence: 99%

“…The methods used to detect ICM in human breast milk range from titration with sodium thiosulphate, to spectrophotometry, UV-spectrometry, Technicon Analyzer and high pressure liquid chromatography (HPLC) (table 1). While older papers detected iodine [6,7,9,10], others directly determined the ICM-molecules and their concentration in the human milk [5,8].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Excretion of iodinated contrast media in human breast milk: surprising results

Boehm

Hungerbühler

2020

European Journal of Radiology

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Excretion of metrizamide in milk

Cited by 29 publications

References 3 publications

The use of iodinated and gadolinium contrast media during pregnancy and lactation

The use of iodinated and gadolinium contrast media during pregnancy and lactation

Excretion of Iohexol and Metrizoate in Human Breast Milk

Excretion of iodinated contrast media in human breast milk: surprising results

Contact Info

Product

Resources

About